These results suggest that fenofibrate may be a potential therapeutic modality to modulate intra-renal AMPK-PGC-1α and FoxO3s signaling to treat type 2 diabetic nephropathy. The gene discussed is PRKAA1; the disease is type 2 diabetes nephropathy.